Search Results

Containing any of the words

Only of the type

A Phase 3, randomized, double-blind, placebo-controlled, parallel-group, 3-arm, multinational, multicenter study to evaluate the efficacy and safety of amlitelimab by subcutaneous injection in participants aged 18 years and older with moderate-to-severe atopic dermatitis (AD) who are on background topical corticosteroids and have had an inadequate response to prior biologic therapy or oral Janus Kinase (JAK) inhibitor treatment Drug Clinical Trial

Saudi FDA Participates in the activities of the 25th. National Heritage & Culture Festival (Janadriyah 25) News

SFDA Closes 7 Non-complying Facilities and Suspends 23 Production Lines in December News

Recall of batch 656089 from the product: BUSULCAN 6 mg/ml Vial Drugs Circulars and withdrawal

(SG-1907-77-H) iLA activve Kits and iLA activve iLA Kit - leak testing of the DP3 pump head Medical Report

(SG-1903-15-H) Potential Risks associated with Vial2Bag Fluid Transfer Sets May Result in Patient Harm Medical Report

A Phase III, Multicenter, Randomized, parallel-group study to asses the efficacy and saftey of double-blind pasireotide LAR 40 mg and pasireotide LAR 60 mg versus open lable octreotide LAR or lanreotide ATG in patients with inadequately controlled acromegaly. Drug Clinical Trial

Randomized, three-way, three-period, single oral dose, open-label, crossover, bioequivalence study to compare Torvacol tablets (20 mg atorvastatin) Produced by JPM / Jordan, versus Lipitor® tablets (20 mg atorvastatin) Produced by Pfizer / Irland in healthy subjects under fasting conditions. Drug Clinical Trial

An open label, Phase IV Multicentric Single Arm Study to Assess the Safety and Efficacy of Croma Ophthalmic Solution Containing Sodium Cromoglycate (40 mg/ml) and Tetrahydrozoline Hydrochloride (0.5 mg/ml) in Subjects with Chronic Allergic Conjunctivitis and Hay Fever (Seasonal) Drug Clinical Trial

An Open Label, Phase IV, Multi-Centric, Prospective, Single Arm Study to Assess the Safety and Efficacy of Loxtra Eye Drops Containing Ofloxacin (3 mg), Prednisolone (2 mg) and Tetrahydrozoline Hydrochloride (0.4 mg) in Subjects with Bacterial Conjunctivitis and Other Ocular Inflammatory Conditions Drug Clinical Trial